IBJ Podcast: Here’s why the feds are suing Community Health with help from a whistleblower
IBJ’s John Russell has written about the Community case and talks with host Mason King about the details, what it means for Community Health and how the lawsuit fits into a larger effort by the federal government to claw back what it considers “unjust enrichment” by hospital systems.Read More
Cash-strapped Indy Parks seeks creative financing for community center
A deal to build a new family center at Broad Ripple Park could be just the first of several privately funded projects considered by the park system.Read More
As injuries mount, Methodist Sports Medicine expands to meet need
Founded in 1983, the practice has 28 physicians and annual revenue of $35 million, and shows little sign of slowing.Read More
The retirement community operator had revenue of $51.4 million last year, up 4% from 2017, according to its Form 990 tax return.
Three years after Indiana passed a law allowing doctors to prescribe drugs for patients without an in-person visit—using a computer, smartphone, video camera and similar technology—some health systems around the state are reporting higher use of virtual visits. St. Vincent, for example, sees hundreds of patients a month remotely for ailments ranging from minor rashes and sprains to follow-up visits for strokes.
Indiana health officials are investigating 30 cases of severe lung injury linked to vaping. Eight of those have been confirmed—most of them among individuals between the ages of 16 and 29. Earlier this month, the state confirmed the first death linked to vaping.
The spinoff, called Sexton Biotechnologies, has raised $5 million in outside investment and will spin off in October. The biotech develops cell and gene therapy tools used to grow cells for medical purposes.
Since the first pager was patented in 1949 and used in New York’s Jewish Hospital, millions of doctors have done their daily rounds in hospitals with the gadget clipped to their waistband, always ready to hear the beep that might signal a medical crisis on the other end. But hospitals are now phasing them out.
Purdue Pharma may have just set the starting point for determining what it will cost dozens of pharmaceutical companies to resolve legal liability over their role in creating the U.S. opioid epidemic.
The device, manufactured in Singapore, won a Mira Award earlier this year for Innovation of the Year, and now its creator said he’s winning over doctors and medical providers with his invention.
President Donald Trump said Wednesday his administration will propose banning thousands of flavors used in e-cigarettes to combat a recent surge in underage vaping.
The new stalled rule would require applicants to have the state health department, not the BMV, sign off on an individual’s attempt to be recognized on their driver’s license or state ID as anything other than their gender at birth.
Last year, Taltz rang up sales of $937.5 million, and doctors are increasingly prescribing it. For the first six months of this year, Taltz recorded $606.3 million in sales, putting it on pace to break the $1 billion threshold, perhaps in the third quarter.
The state, which ranks third worst in the nation in maternal mortality, said it will use the money to develop ways to prevent or manage maternal illness.
After building and selling three companies and starting a fourth, Dr. Don Brown thought he had seen it all. Even so, he still gets an occasional surprise.
The treatment costs $375,000 or $475,000, depending on whether it is used for advanced lymphoma or pediatric leukemia. Hospital stays can add hundreds of thousands of dollars to the cost of care.
Prescriptions of the overdose-reversing drug naloxone are soaring, and experts say that could be a reason overdose deaths have stopped rising for the first time in nearly three decades.
A prescription drug compromise that would lower costs for Medicare recipients and save billions for Medicare and Medicaid cleared a key hurdle in the Senate on Thursday.
The meeting occurred as a bipartisan effort is underway in the Senate that two of its sponsors say would lead to $100 billion in savings on prescription-drug spending over a decade.